Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.37 CAD | +4.41% | -7.42% | +464.29% |
01:35pm | Medicenna to Present Clinical Update on MDNA11 ABILITY-1 Trial at Sachs Oncology Innovation Forum | MT |
May. 13 | Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+464.29% | 130M | |
+44.48% | 55.07B | |
-0.86% | 41.79B | |
+44.13% | 40.22B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |
- Stock Market
- Equities
- MDNA Stock
- News Medicenna Therapeutics Corp.
- Medicenna Commences Enrollment in ABILITY-1 Study Combining MDNA11 with Pembrolizumab